Is Aprea Therapeutics Stock a Buy?
Investing in biotech stocks focused on experimental oncological therapies is risky enough. What's even more perilous is buying a biotech stock that will make or break on one such candidate alone. Indeed, the probability that an experimental candidate can progress from phase 1 to approval stands at only 10%.
Although it can seem risky to invest in small-cap companies, this goes against one of Warren Buffet's core investment principles: "We simply attempt to be fearful when others are greedy and to be greedy only when others are fearful." Today, let's look at one such company, Aprea Therapeutics (NASDAQ: APRE), and why it is more likely than not to advance its only possible cancer treatment to market, and subsequently deliver riches for investors.
Image Source: Getty Images
Source Fool.com
